Miniatura

Fitxers

bonovas2016_2764.pdf (782.21 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2016-01

Llicència de publicació

cc by-nd (c) Bonovas et al., 2016
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/118799

Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

http://dx.doi.org/10.1097/MD.0000000000002308

Resum

Anemia is the most prevalent extraintestinal complication of inflammatory bowel disease (IBD). Our aim was to evaluate the comparative efficacy and harm of intravenous (IV) versus oral iron supplementation for correcting anemia in adult IBD patients. We conducted a systematic review and meta-analysis to integrate evidence from randomized controlled trials having enrolled adults with IBD, and comparing IV versus oral iron (head-to-head) for correcting iron-deficiency anemia. Medline, Embase, Scopus, and the Web of Science database were searched through July 2015. The Cochrane Central Register of Controlled Trials, the WHO International Clinical Trials Registry Platform, the ClinicalTrials.gov, and international conference proceedings were also investigated. Two reviewers independently abstracted study data and outcomes, and rated each trial's risk-of-bias. Pooled odds ratio (OR) estimates with their 95% CIs were calculated using fixed- and random-effects models. Five eligible studies, including 694 IBD patients, were identified. In meta-analysis, IV iron demonstrated a higher efficacy in achieving a hemoglobin rise of ≥2.0 g/dL as compared to oral iron (OR: 1.57, 95% CI: 1.13, 2.18). Treatment discontinuation rates, due to adverse events or intolerance, were lower in the IV iron groups (OR: 0.27, 95% CI: 0.13, 0.59). Similarly, the occurrence of gastrointestinal adverse events was consistently lower in the IV iron groups. On the contrary, serious adverse events (SAEs) were more frequently reported among patients receiving IV iron preparations (OR: 4.57, 95% CI: 1.11, 18.8); however, the majority of the reported SAEs were judged as unrelated or unlikely to be related to the study medication. We found no evidence of publication bias, or between-study heterogeneity, across all analyses. Risk of bias was high across primary studies, because patients and personnel were not blinded to the intervention. IV iron appears to be more effective and better tolerated than oral iron for the treatment of IBD-associated anemia.

Matèries

Anèmia, Malalties inflamatòries intestinals

Matèries (anglès)

Anemia, Inflammatory bowel diseases

Citació

Col·leccions

Articles publicats en revistes (ISGlobal)

Citació

BONOVAS, Stefanos, FIORINO, Gionata, ALLOCCA, Mariangela, LYTRAS, Theodore, TSANTES, Argirios, PEYRIN-BIROULET, Laurent, DANESE, Silvio. Intravenous Versus Oral Iron for the Treatment of Anemia in
                Inflammatory Bowel Disease: A Systematic Review and
                Meta-Analysis of Randomized Controlled Trials. _Medicine_. 2016. Vol. 95, núm. 2, pàgs. e2308. [consulta: 24 de gener de 2026]. ISSN: 0025-7974. [Disponible a: https://hdl.handle.net/2445/118799]

Exportar metadades

JSON - METS

Compartir registre